- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cartesian Therapeutics Inc (RNAC)
Track today's live Cartesian Therapeutics (RNAC) share price, performance and key data on this page with our current NASDAQ:RNAC stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Cartesian Therapeutics share price on the NASDAQ exchange. Use the dropdown to switch exchange for the RNAC share price, head to our technical summary section, which provides analysis on Cartesian Therapeutics share price buy/sell indicators using real-time data (or discuss the Cartesian Therapeutics (RNAC) stock price today with other investors in the Cartesian Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:RNAC share price (ISIN: US8162123025) to enhance your trading decisions with our free investment tools and resources.
What Is the Cartesian Therapeutics Inc Share Price Today?
The Cartesian Therapeutics share price today is 9.270.
What Is the Stock Symbol for Cartesian Therapeutics Inc
The stock symbol (or 'ticker') for Cartesian Therapeutics Inc is "RNAC."
What Stock Exchange Does Cartesian Therapeutics Inc Trade On?
Cartesian Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Cartesian Therapeutics Inc a Good Stock to Buy?
Determining whether Cartesian Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:RNAC share price (ISIN: US8162123025) to enhance your trading decisions with our free investment tools and resources.
What Is the Cartesian Therapeutics Inc Share Price Today?
The Cartesian Therapeutics share price today is 9.270.
What Is the Stock Symbol for Cartesian Therapeutics Inc
The stock symbol (or 'ticker') for Cartesian Therapeutics Inc is "RNAC."
What Stock Exchange Does Cartesian Therapeutics Inc Trade On?
Cartesian Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Cartesian Therapeutics Inc a Good Stock to Buy?
Determining whether Cartesian Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.890
9.310
52 wk Range
5.600
11.000
RNAC is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.8909.310
52 wk Range
5.60011.000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RNAC Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
34.571
Upside
+272.94%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 34.571
(+272.94% Upside)
Earnings
Latest Release
06/08/2026
EPS / Forecast
0.46 / -0.88
Revenue / Forecast
164K / 179.67K
Compare RNAC to Peers and Sector
Metrics to compare | RNAC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRNACPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.8x | −3.7x | −0.4x | |
PEG Ratio | 0.01 | −0.07 | 0.00 | |
Price/Book | −2.2x | 2.8x | 2.6x | |
Price / LTM Sales | 189.9x | 8.7x | 3.0x | |
Upside (Analyst Target) | 320.7% | 251.6% | 49.0% | |
Fair Value Upside | Unlock | 14.3% | 6.5% | Unlock |
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Cartesian Therapeutics (NASDAQ: RNAC) Share Price Today?
The Cartesian Therapeutics stock price today is 9.270 USD.
What Stock Exchange Does Cartesian Therapeutics (RNAC) Trade On?
Cartesian Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Cartesian Therapeutics?
The stock symbol (also called a 'ticker') for Cartesian Therapeutics is "RNAC."
What Is the Current Cartesian Therapeutics Market Capitalisation?
As of today, Cartesian Therapeutics (NASDAQ: RNAC) market cap is 280.470M USD.
What Is Cartesian Therapeutics's (RNAC) Earnings Per Share (TTM)?
The Cartesian Therapeutics EPS is currently -5.612 (Trailing Twelve Months).
When Is the Next Cartesian Therapeutics Earnings Date?
Cartesian Therapeutics's next earnings report will be released on 05/11/2026.
Is RNAC a Buy or Sell From a Technical Analyst Perspective?
Based on today's Cartesian Therapeutics moving averages and other technical indicators, the daily buy/sell signal for RNAC stock is Neutral.
How Many Times Has Cartesian Therapeutics Stock Split?
Cartesian Therapeutics has split 1 times. (See the RNAC stock split history page for full effective split date and price information.)
How Many Employees Does Cartesian Therapeutics Have?
Cartesian Therapeutics has 75 employees, based on their latest Companies House report.
What is the current trading status of Cartesian Therapeutics (NASDAQ: RNAC)?
As of 08/09/2026, Cartesian Therapeutics (RNAC) is trading at a share price of 9.270 USD, with a previous close of 9.120 USD. The stock has fluctuated within a day range of 8.890 USD to 9.310 USD, while its 52-week range spans from 5.600 USD to 11.000 USD.
What Is Cartesian Therapeutics (RNAC) Price Target According to Analysts?
The average 12-month price target for Cartesian Therapeutics is 34.571 USD, with a high estimate of 44 USD and a low estimate of 16 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +272.94% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.